Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADx-001 MRI for Brain Amyloid Detection
NCT05453539Phase 1Terminated
- Sponsor
- Alzeca Biosciences
- Start
- Nov 2022
- Primary completion
- Nov 2024
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label trial of DSPE-DOTA-Gd in Alzheimer's disease (AD) (5 arms), sponsored by Alzeca Biosciences. Primary endpoint: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0. Started Nov 2022; status: terminated.
02
Drugs
DSPE-DOTA-Gd
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05453539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05453539.